| Cat. No. |
Product Name |
Information |
| PC-45735 |
3PO
PFKFB3 inhibitor
|
PFKFB3 inhibitor 3PO is a small-molecule, competitive inhibitor of PFKFB3 isozyme with IC50 of 23 uM. |
| PC-45384 |
Amcasertib
Cancer stem cells inhibitor
|
Amcasertib (BBI503) is a small-molecule inhibitor that inhibits Nanog and other CSC (cancer stem cells) pathways by targeting kinases. |
| PC-45557 |
RR6
Vanin inhibitor
|
RR6 is a selective, reversible, and competitive Vanin inhibitor with IC50 of 0.54 uM for hVVN1 pantetheinase (vanin-1). |
| PC-45331 |
Bromethalin
|
Bromethalin is a rodenticide that poisons the central nervous system by uncoupling mitochondrial oxidative phosphorylation, which causes a decrease in adenosine triphosphate (ATP) synthesis. |
| PC-42291 |
Conduritol B epoxide
β-glucosidase inhibitor
|
Conduritol B epoxide is a potent, specific, irreversible glucocerebrosidase (acid β-glucosidase) inhibitor with Ki of 53 uM. |
| PC-42264 |
Rbin-1
Midasin inhibitor
|
Rbin-1 (Ribozinoindole-1) is a potent, specific and reversible inhibitor of eukaryotic ribosome biogenesis that targets the AAA+ protein Midasin (IC40=1 uM). |
| PC-42268 |
TN1
HbF inducer
|
TN1 is a potent, small molecule fetal hemoglobin (HbF) inducer with EC50 of 100 nM. |
| PC-42279 |
PF-1355
MPO inhibitor
|
PF-1355 (PF-06281355) is a potent, selective, orally active Myeloperoxidase (MPO) inhibitor with EC50 of 1.47 uM. |
| PC-45669 |
GSK2256294A
sEH inhibitor
|
GSK2256294A is a potent, selective soluble epoxide hydrolase (sEH, EPHX2) inhibitor with IC50 of 27/61/189 pM for recombinant human/rat/mouse sEH, respectively. |
| PC-45486 |
DZ2002
SAHH inhibitor
|
DZ2002 is a potent, reversible type III inhibitor of SAHH (S-adenosyl-L-homocysteine hydrolase) with Ki of 17.9 nM. |
| PC-45053 |
CH-5450
Chymase inhibitor
|
CH-5450 is a potent, peptide-inhibitor of human chymase with Ki of 1 nM. |
| PC-45604 |
PF-06282999
MPO inhibitor
|
PF-06282999 is a potent, highly selective and irreversible inhibitor of myeloperoxidase (MPO) with Kinact/KI of 116000 M-1s-1. |
